{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0014756\nAge: 45\nGender: Male\nSample ID: P-0014756-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Prostate Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 80.0%\n=============\nDNA Variants:\nAXIN1 c.1603G>A (p.V535I) - in 42.00% of 1074 reads\nBCL10 c.499del (p.S167Lfs*6) - in 38.00% of 594 reads\nBRCA1 c.3805G>A (p.D1269N) - in 39.00% of 698 reads\nBRD4 c.1235A>G (p.Y412C) - in 39.00% of 795 reads\nCASP8 c.1596dupA (p.L533Tfs*6) - in 34.00% of 655 reads\nCD79A c.390del (p.R131Gfs*61) - in 37.00% of 485 reads\nCHEK2 c.844C>A (p.H282N) - in 36.00% of 433 reads\nCYLD c.2156del (p.N719Mfs*13) - in 6.00% of 562 reads\nDOT1L c.3106G>T (p.D1036Y) - in 40.00% of 912 reads\nERF c.157G>A (p.G53R) - in 35.00% of 877 reads\nFAT1 c.4675G>A (p.A1559T) - in 43.00% of 652 reads\nKDM5A c.3754C>T (p.R1252C) - in 56.00% of 670 reads\nMDC1 c.803G>T (p.R268M) - in 39.00% of 847 reads\nMED12 c.6285_6287delACA (p.Q2115del) - in 5.00% of 205 reads\nMGA c.7731delA (p.D2578Tfs*10) - in 59.00% of 351 reads\nMLL4 c.1942C>T (p.R648W) - in 37.00% of 705 reads\nMYC c.1261G>C (p.V421L) - in 44.00% of 1037 reads\nNCOR1 c.2319dupA (p.P774Tfs*3) - in 40.00% of 797 reads\nNFE2L2 c.1719_1729dupAAAACCTTATT (p.S577*) - in 21.00% of 743 reads\nNFE2L2 c.1707_1711dupTGATG (p.E571Vfs*43) - in 22.00% of 792 reads\nNOTCH4 c.5002C>T (p.R1668C) - in 42.00% of 811 reads\nPOLD1 c.2209T>A (p.S737T) - in 37.00% of 723 reads\nPOLD1 c.1859C>T (p.T620M) - in 40.00% of 942 reads\nRET c.260G>A (p.C87Y) - in 36.00% of 745 reads\nRET c.1078C>T (p.R360W) - in 38.00% of 716 reads\nSETD2 c.4873C>T (p.R1625C) - in 42.00% of 1239 reads\nSMARCB1 c.946C>T (p.R316W) - in 37.00% of 739 reads\nSMO c.584T>C (p.V195A) - in 20.00% of 1592 reads\nTGFBR2 c.470C>T (p.T157I) - in 45.00% of 916 reads\nTP53BP1 c.2145del (p.E716Nfs*12) - in 35.00% of 976 reads\nCNA Data:\nEPCAM - Homozygous Deletion\nKDM6A - Homozygous Deletion\nAR - High Level Amplification\nStructural Variants:\nMSH2 - MSH2 (DELETION)\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Metastatic Castration-Resistant Prostate Cancer\",\n    \"Disease Phase or Condition\": \"Metastatic CRPC with homologous recombination repair (HRR) gene mutations\",\n    \"Drug Name\": \"Olaparib\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Genomic Features\": [\n      \"BRCA1\",\n      \"CHEK2\",\n      \"PALB2\",\n      \"RAD54L\"\n    ],\n    \"FDA-approval status\": \"FDA-approved for adult patients with deleterious or suspected deleterous germline or somatic HRR gene mutations in mCRPC who have progressed following prior treatment with enzalutamide or abiraterone\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n  }\n}"
}